Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.


Investor Contact:

Priyam Shah
investors@akoyabio.com

Media Contact:

Christine Quern
media@akoyabio.com

Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.95
+3.86 (1.75%)
AAPL  263.64
+4.06 (1.56%)
AMD  250.97
+15.97 (6.80%)
BAC  52.58
+0.82 (1.57%)
GOOG  262.09
+8.36 (3.29%)
META  737.99
+3.99 (0.54%)
MSFT  524.63
+4.07 (0.78%)
NVDA  185.28
+3.12 (1.71%)
ORCL  284.51
+4.44 (1.59%)
TSLA  434.15
-14.83 (-3.30%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.